3689 (3689) Fair Value & Analysis

Healthcare · Market cap HK$512M

3 3689 3689 · HK

PriceHK$1.53

Fair ValueHK$6.41

Upside+319.0%

Quality60/100

Watch 3689 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$4.74 – HK$8.08

Fair value as of: Jul 2, 2026

From 25 valuation models · updated today

Share price −10.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.46 – HK$2.02 · fair‑value band HK$4.74 – HK$8.08 · the HK$1.53 price screens below the HK$6.41 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3689 (3689) currently trades at HK$1.53, while our model-based Fair Value estimate is HK$6.41 — implying the stock looks roughly 319.0% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 3689 generated revenue of HK$2.0B at a net margin of 4.9%. Revenue declined 2.7% year over year. It earns a return on equity of 6.3%. Net debt stands at HK$92.5M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.0B

Revenue growth (YoY) -2.7%

Net margin 4.9%

Return on equity 6.3%

Free cash flow HK$234M FY2025

P/E ratio 4.5

More key figures

Operating margin 10.4%

EPS (TTM) HK$0.1200

Dividend yield 10.5%

EPS growth (YoY) +66.3%

Net debt HK$92.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3689 reported revenue of HK$2.0B in FY2025 versus HK$2.0B in FY2021, a compound +0.2%/yr. Reported net income was HK$97.0M in FY2025, compounding +0.7%/yr from FY2021.

Revenue +0.2%/yr

FY21 HK$2.0B

FY22 HK$1.8B

FY23 HK$2.0B

FY24 HK$2.1B

FY25 HK$2.0B

Net income +0.7%/yr

FY21 HK$94.3M

FY22 HK$59.7M

FY23 HK$121M

FY24 HK$15.3M

FY25 HK$97.0M

Is 3689 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3689 (3689) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$6.41 versus a price of HK$1.53 — about +319% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 3689?

Our model-based fair value for 3689 is HK$6.41 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.53.

What is the quality score of 3689?

3689 has a Quality Score of 60/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3689 (3689)?

3689 reported trailing-twelve-month revenue of about HK$2.0B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3689?

The net profit margin of 3689 is about 4.9%, meaning it keeps roughly 4.9% of revenue as net income. Based on the latest reported figures.

Does 3689 pay a dividend?

3689 currently shows a dividend yield of about 10.46% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.